- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00929864
Abatacept Versus Adalimumab Head-to-Head
3 januari 2014 uppdaterad av: Bristol-Myers Squibb
A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis
The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
869
Fas
- Fas 3
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Cordoba, Argentina, 5000
- Local Institution
-
San Juan, Argentina, 5400
- Local Institution
-
Tucuman, Argentina, 4000
- Local Institution
-
-
Buenos Aires
-
Ciudad Autonoma, Buenos Aires, Argentina, CP1425A WC
- Local Institution
-
Ciudad Autonoma De Beunos Aire, Buenos Aires, Argentina, 1431
- Local Institution
-
Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina, 1015
- Local Institution
-
Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina, C1428DQG
- Local Institution
-
Quilmes, Buenos Aires, Argentina, 1878
- Local Institution
-
-
Cordoba
-
Cordoba, Crd, Cordoba, Argentina, X5016KEH
- Local Institution
-
-
Santa Fe
-
Rosario, Santa Fe, Argentina, 2000
- Local Institution
-
-
Tucuman
-
San Miguel De Tucuman, Tucuman, Argentina, 4000
- Local Institution
-
-
-
-
Providencia
-
Santiago, Providencia, Chile
- Local Institution
-
-
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35294
- University of Alabama at Birmingham
-
Birmingham, Alabama, Förenta staterna, 35205
- Rheumatology Associates, Pc
-
Tuscaloosa, Alabama, Förenta staterna, 35406
- Clinical and Translational Research Center of Alabama, PC
-
-
Arizona
-
Peoria, Arizona, Förenta staterna, 85381
- Sun Valley Arthritis Center, Ltd.
-
-
Arkansas
-
Hot Springs, Arkansas, Förenta staterna, 71913
- Mercy Clinic Hot Springs Communities
-
-
California
-
Huntington Beach, California, Förenta staterna, 92646
- Talbert Medical Group
-
La Jolla, California, Förenta staterna, 92037
- Allergy & Rheumatology Medical Clinic, Inc.
-
Long Beach, California, Förenta staterna, 90806
- Valerius Med Group & Res Ctr Of Greater Long Beach, Inc.
-
Pasadena, California, Förenta staterna, 91107
- Irene Y. Tong
-
San Diego, California, Förenta staterna, 92108
- San Diego Arthritis Medical Clinic
-
Torrance, California, Förenta staterna, 90503
- Healthcare Partners Medical Group
-
Torrance, California, Förenta staterna, 90505
- Drs. Goldin, Nies, Klashman & Eng
-
Upland, California, Förenta staterna, 91786
- Inland Rheumatology & Osteoporosis Medical Group
-
-
Florida
-
Aventura, Florida, Förenta staterna, 33180
- Arthritis and Rheumatic Disease Specialties
-
Gainesville, Florida, Förenta staterna, 32610
- University Of Florida College Of Medicine At Jacksonville
-
Miami, Florida, Förenta staterna, 33173
- Center for Arthritis and Rheumatic Diseases
-
Palm Harbor, Florida, Förenta staterna, 34684
- Arthritis Research Of Florida, Inc.
-
Sarasota, Florida, Förenta staterna, 34239
- Sarasota Arthritis Research Center
-
South Miami, Florida, Förenta staterna, 33143
- Miami Research Associates
-
Tamarac, Florida, Förenta staterna, 33321
- West Broward Rheumatology Associates
-
Venice, Florida, Förenta staterna, 34292
- Lovelace Scientific Resources, Inc
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30342
- Arthritis & Rheumatology of Georgia
-
Atlanta, Georgia, Förenta staterna, 30342
- Laureate Clinical Research Group
-
Gainesville, Georgia, Förenta staterna, 30501
- Arthritis Center of North Georgia
-
-
Idaho
-
Boise, Idaho, Förenta staterna, 83702
- St. Luke's Clinic - Rheumatology
-
Coeur D Alene, Idaho, Förenta staterna, 83814
- Coeur D'Alene Arthrit Clin
-
-
Illinois
-
Quincy, Illinois, Förenta staterna, 62301
- Quincy Medical Group
-
Rockford, Illinois, Förenta staterna, 61107
- Rockford Orthopedic Associates, Ltd.
-
-
Iowa
-
Cedar Rapids, Iowa, Förenta staterna, 52401
- Physicians Clinic of Iowa
-
-
Kentucky
-
Elizabethtown, Kentucky, Förenta staterna, 42701
- Center For Arthritis and Osteoporosis
-
Lexington, Kentucky, Förenta staterna, 40504
- Bluegrass Community Research, Inc.
-
-
Maryland
-
Cumberland, Maryland, Förenta staterna, 21502
- Klein And Associates, M.D., Pa
-
Wheaton, Maryland, Förenta staterna, 20902
- The Center For Rheumatology And Bone Research
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02115
- Brigham and Women's Hospital
-
Mansfield, Massachusetts, Förenta staterna, 02048
- Mansfield Health Center
-
-
Michigan
-
Battle Creek, Michigan, Förenta staterna, 49015
- Associated Internal Medicine Specialists
-
Kalamazoo, Michigan, Förenta staterna, 49009
- Rheumatology Pc
-
-
Mississippi
-
Jackson, Mississippi, Förenta staterna, 39202
- Arthritis Associates Of Mississippi
-
-
Missouri
-
St.Louis, Missouri, Förenta staterna, 63131
- Physician Groups, Lc Dba
-
-
Nevada
-
Reno, Nevada, Förenta staterna, 89502
- Arthritis Center of Reno
-
-
New Hampshire
-
Dover, New Hampshire, Förenta staterna, 03820
- Seacoast Arthritis And Osteoporosis Center
-
Nashua, New Hampshire, Förenta staterna, 03060
- Nashua Rheumatology
-
-
New Mexico
-
Las Cruces, New Mexico, Förenta staterna, 88011
- Arthritis and Osteoporosis Associates of New Mexico
-
-
New York
-
Lake Success, New York, Förenta staterna, 11042
- North Shore Lij Health System
-
Mineola, New York, Förenta staterna, 11501
- Winthrop University Hospital
-
Smithtown, New York, Förenta staterna, 11787
- Rheumatology Associates of Long Island
-
-
North Carolina
-
Asheville, North Carolina, Förenta staterna, 28803
- Asheville Rheumatology & Osteoporosis Research Asso P. A.
-
Statesville, North Carolina, Förenta staterna, 28625
- Carolina Pharmaceutical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73109
- Health Research Institute
-
Oklahoma City, Oklahoma, Förenta staterna, 73103
- Health Research of Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73112
- Lynn Health Sciences Institute
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Förenta staterna, 18015
- East Penn Rheumatology Associates, P.C.
-
Duncansville, Pennsylvania, Förenta staterna, 16635
- Altoona Center for Clinical Research
-
Wyomissing, Pennsylvania, Förenta staterna, 19610
- Clinical Research Center of Reading, LLP
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29406
- Low Country Rheumatology, PA
-
Columbia, South Carolina, Förenta staterna, 29204
- Columbia Arthritis Center, P.A.
-
-
Texas
-
Austin, Texas, Förenta staterna, 78758
- Lovelace Scientific Resources, Inc.
-
Dallas, Texas, Förenta staterna, 75246
- Arthritis Centers Of Texas
-
Houston, Texas, Förenta staterna, 77004
- Rheumatic Disease Clinical Research Center, LLC
-
-
Virginia
-
Chesapeake, Virginia, Förenta staterna, 23320
- Center For Arthritis & Rheumatic Diseases, Pc
-
-
Washington
-
Spokane, Washington, Förenta staterna, 99202
- Rockwood Research Center
-
-
West Virginia
-
Clarksburg, West Virginia, Förenta staterna, 26301
- Mountain State Clinical Research
-
-
Wisconsin
-
Glendale, Wisconsin, Förenta staterna, 53217
- Rheumatic Disease Center
-
-
-
-
-
Quebec, Kanada, G1V 3M7
- Local Institution
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3A 1M3
- Local Institution
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8N 1Y2
- Local Institution
-
-
Quebec
-
Trois-Rivieres, Quebec, Kanada, G8Z 1Y2
- Local Institution
-
-
-
-
-
Lima, Peru
- Local Institution
-
Lima, Peru, LIMA 11
- Local Institution
-
Lima, Peru, LIMA 33
- Local Institution
-
Lima, Peru, LIMA 27
- Local Institution
-
-
Callao 2
-
Bellavista, Callao 2, Peru
- Local Institution
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Moderate to severe Rheumatoid arthritis (RA) according to American College of Rheumatology (ACR) criteria
- Methotrexate failure
- Naive to RA biologics
- ≤5 years duration of disease
- Disease Activity Score-28 C-reactive protein (DAS28 CRP) ≥ 3.2
- Willingness to self-inject subcutaneous (SC) drug
Exclusion Criteria:
- Previous or current medical conditions that are warnings against the use of tumor necrosis factor (TNF)-blocking agents
- History of active or chronic hepatitis
- Cancer in the last 5 years
- History of severe chronic or recurrent bacterial or viral infections
- Risk of tuberculosis
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, Gastro-intestinal, pulmonary, cardiac, neurologic, or cerebral disease
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Adalimumab
|
Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
Andra namn:
|
|
Aktiv komparator: Abatacept
|
Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
The Proportion of Participants Meeting the American College of Rheumatology (ACR) Criteria of 20% Improvement (ACR20) After 12 Months of Treatment - Intent to Treat Population
Tidsram: Day 1 to Day 365
|
Proportion(%)=number of participants meeting criteria (n) divided by number of participants who received drug (N).
The ACR score indicates degree of improvement in a patient's rheumatoid arthritis (RA), based on guidelines set forth by the ACR and represents a percentage.
To qualify a ACR20 score, patient must have >=20% fewer tender joints and >=20% fewer swollen joints and show 20% improvement from baseline in at least 3 of: patient overall assessment of his/her RA, physician global assessment of the patient's RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein (CRP) test (to assess inflammation).
Baseline was Day 1. Randomization was stratified using screening Disease Activity Score-28 (DAS28) CRP, a composite of 4 variables: number of tender joints/28, number of swollen joints/28, CRP in mg/L and participant assessment of disease activity with visual analogue scale.
|
Day 1 to Day 365
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of Participants With Local Injection Site Reactions Adverse Events (Pre-specified) Reported During 12 Month Period - ITT Population
Tidsram: Day 1 to 12 Months
|
n=number of participants with a pre-specified local injection site reaction event, N=number of participants at risk.
Proportion (%) = n/N.
12 Months includes data up to 56 days post last dose of the first 12 months Period or start of the first dose of second 12 months period.
|
Day 1 to 12 Months
|
|
Incidence Rate of Local Injection Site Reactions (Pre-specified) Reported During 24 Month Period - ITT Population
Tidsram: Day 1 to Day 729
|
Incidence Rate: (incidence/100 person-years) = number of participants with event * 100 /exposure (person-years) Exposure (person-years) = the sum over all participants of the exposure per participant in the 24 months (censored at the time of first occurrence of AE) expressed in days, divided by 365.25.
The 24 Month Period includes data up to 56 days post the last dose in the 24 month period.
Poisson distribution used to construct the 95% CIs.
|
Day 1 to Day 729
|
|
Proportion of Participants Without Radiographic Progression in Total Score Less Than or Equal to the Smallest Detectable Change (SDC) From Baseline to Months 12 and 24 Using Modified Van Der Heijde Total Sharp Score (mSvdHS) - ITT Population
Tidsram: Baseline to Day 729
|
Plain radiographs of hands and feet taken at baseline (BL), Day 365, and Day 729.
BL and Day 365 radiographs were re-read concurrent with Day 729 films by readers blinded to sequence and treatment (a second pre-specified reading campaign).
SDC defined as amount of change for which anything smaller could not be reliably distinguished from random error in measurement of simultaneously read films.
Non-progression defined: change from BL (Day 1, prior to dosing) in total score less than, equal to (<=) SDC(2.2).
Proportion n/m (%)=number meeting criteria (n); number analyzed (m).
SDC calculated as SD/sqrt(2)*1.96/sqrt(2)with
standard deviation (SD) of paired differences of change from BL in total score between 2 readers; squared root(sqrt).
mSvdHS=summary of erosion severity in 32 hand and 12 foot joints.
Hand joints scored 0 to 5; foot joints 0 to 10 with 0=no erosion and higher numbers indicating greater erosion severity.
BL: radiographic data within 14 days or less of first dose.
|
Baseline to Day 729
|
|
Incidence Rate of Serious Adverse Events (SAEs), Serious Infections, Pre-specified Opportunistic Infections, and Discontinuation for Any Cause at 12 Months of Treatment - ITT Population
Tidsram: Day 1 to Day 365
|
Pre-specified opportunistic infections include: pneumonia, tuberculosis, herpes zoster, combined opportunistic infections, all hospitalized infections.
Incidence Rate: incidence/100 person-years: numerator was number of unique events within this period (up to 56 days post-last dose of first 12 months or start of first dose of second 12 months); denominator was overall total exposure (person-years) within this period, calculated as sum over all participants of exposure (in days) divided by 365.25.
The resulting incidence rate was multiplied by 100 to express rate per 100 person-years.
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
|
Day 1 to Day 365
|
|
Incidence Rate of Serious Adverse Events (SAEs), Serious Infections, Pre-specified Opportunistic Infections, and Discontinuation for Any Cause at 24 Months of Treatment - ITT Population
Tidsram: Day 1 to Day 729
|
Pre-specified opportunistic infections include: pneumonia, tuberculosis, herpes zoster, combined opportunistic infections, and all hospitalized infections.
Incidence Rate: incidence/100 person-years: numerator was number of unique events within this period (up to 56 days post the last dose of the 24 Months period); denominator was overall total exposure (person-years) within this period, which was calculated as the sum over all participants of exposure (in days) divided by 365.25.
The resulting incidence rate was multiplied by 100 to express the rate per 100 person-years.
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
|
Day 1 to Day 729
|
|
Proportion of Participants With Induction of Autoantibodies During the 12 Months and 24 Months Periods - ITT Population
Tidsram: Day 1 to Day 729
|
The induction of autoantibodies was defined as participant's antinuclear antibodies (ANA) or anti-double stranded deoxyribonucleic acid (dsDNA) converting from a negative status at baseline to a positive status at a post-baseline measurement time point (Day 365 or Day 729).
Proportion (%) = n/m, where n=number of participants with positive ANA or dsDNA at a time point and m=number of participants who had negative ANA or dsDNA at baseline.
Blood samples were first tested for ANA by indirect fluorescent assay using HEp-2 Cell Line Substrate, and when positive, samples were further tested for anti-dsDNA by indirect fluorescent assay using Crithidia Luciliae Substrate.
|
Day 1 to Day 729
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Allmänna publikationer
- Keystone EC, Ahmad HA, Yazici Y, Bergman MJ. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. Rheumatology (Oxford). 2020 Aug 1;59(8):2090-2098. doi: 10.1093/rheumatology/kez455.
- Jabado O, Maldonado MA, Schiff M, Weinblatt ME, Fleischmann R, Robinson WH, He A, Patel V, Greenfield A, Saini J, Galbraith D, Connolly SE. Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis. Rheumatol Ther. 2022 Apr;9(2):391-409. doi: 10.1007/s40744-021-00404-x. Epub 2021 Dec 8.
- Fleischmann R, Weinblatt M, Ahmad H, Maldonado MA, Alemao E, Ye J, Schiff M. Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). Rheumatol Ther. 2019 Dec;6(4):559-571. doi: 10.1007/s40744-019-00174-7. Epub 2019 Oct 22.
- Fleischmann R, Connolly SE, Maldonado MA, Schiff M. Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab. Arthritis Rheumatol. 2016 Sep;68(9):2083-9. doi: 10.1002/art.39714.
- Schiff M, Weinblatt ME, Valente R, Citera G, Maldonado M, Massarotti E, Yazici Y, Fleischmann R. Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration. RMD Open. 2016 Apr 19;2(1):e000210. doi: 10.1136/rmdopen-2015-000210. eCollection 2016.
- Fleischmann R, Weinblatt ME, Schiff M, Khanna D, Maldonado MA, Nadkarni A, Furst DE. Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 Jul;68(7):907-13. doi: 10.1002/acr.22763.
- Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, Zhu J, Maldonado MA, Patel S, Robinson WH. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2016 Apr;75(4):709-14. doi: 10.1136/annrheumdis-2015-207942. Epub 2015 Sep 10.
- Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014 Jan;73(1):86-94. doi: 10.1136/annrheumdis-2013-203843. Epub 2013 Aug 20.
- Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013 Jan;65(1):28-38. doi: 10.1002/art.37711.
Användbara länkar
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 oktober 2009
Primärt slutförande (Faktisk)
1 oktober 2011
Avslutad studie (Faktisk)
1 november 2012
Studieregistreringsdatum
Först inskickad
29 juni 2009
Först inskickad som uppfyllde QC-kriterierna
29 juni 2009
Första postat (Uppskatta)
30 juni 2009
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
4 februari 2014
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
3 januari 2014
Senast verifierad
1 januari 2014
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Immunsystemets sjukdomar
- Autoimmuna sjukdomar
- Ledsjukdomar
- Muskuloskeletala sjukdomar
- Reumatiska sjukdomar
- Bindvävssjukdomar
- Artrit
- Artrit, reumatoid
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Antiinflammatoriska medel
- Antireumatiska medel
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Immune Checkpoint-hämmare
- Adalimumab
- Abatacept
Andra studie-ID-nummer
- IM101-235
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .